Medtronic Completes Acquisition of CathWorks

April 20, 2026—Medtronic announced it has completed its acquisition of CathWorks, a privately held medical device company focused on the diagnosis and treatment of coronary artery disease with its fractional flow reserve (FFR) diagnostic technology.

The company first announced it was exercising its option to acquire CathWorks in a transaction valued at $585 million with potential undisclosed earn-out payments postacquisition in February 2026. In 2022, Medtronic announced a strategic partnership with a copromotion agreement for the CathWorks FFRangio system in the United States, Europe, and Japan, where it is commercially available.

Medtronic stated that the merger completion comes soon after the 1-year results from CathWorks’ ALL-RISE randomized controlled trial were presented at ACC.26, the American College of Cardiology’s annual scientific session and simultaneously published by William F. Fearon, MD, et al in The New England Journal of Medicine.

The ALL-RISE trial enrolled more than 1,900 patients across 59 sites in North America, Asia, Europe, and the Middle East. demonstrated that CathWorks FFRangio is noninferior to wire-based physiology in terms of major adverse cardiac events at 1 year, with improved resource utilization and reduced procedure time benefits, advised the company.

The CathWorks FFRangio system uses a combination of artificial intelligence and advanced computational science to provide a comprehensive physiological assessment of the entire coronary tree directly from routine drug-free, wire-free coronary angiograms, noted Medtronic.

Jason Weidman, Senior Vice President and President of the Coronary & Renal Denervation business, part of the Cardiovascular Portfolio at Medtronic, commented on the transaction in the company’s press release.

“The acquisition of CathWorks significantly enhances Medtronic’s interventional cardiology portfolio with an innovative system that empowers physicians with data-driven insights for the diagnosis and treatment of coronary artery disease,” stated Weidman. “Through our global footprint, welcoming CathWorks to Medtronic will expand access to the transformative FFRangio technology for our customers and their patients worldwide.”